<DOC>
	<DOCNO>NCT00703651</DOCNO>
	<brief_summary>This follow-up previous dose-ranging study aim investigate 2 dos trivalent inactivated split virion influenza vaccine administer intradermal route current pharmaceutical presentation administer intramuscular route . Primary Objective : To assess immunogenicity two pharmaceutical presentation trivalent inactivate split virion influenza vaccine 21 day single injection subject age 18 57 year . Secondary Objective : To evaluate safety profile 21-day period follow vaccination study group</brief_summary>
	<brief_title>Study Inactivated , Split-Virion Influenza Vaccine Administered Intradermal Route Versus Vaxigrip® Adults</brief_title>
	<detailed_description>This open ( administration route ) double-blind ( two dosage administer year 0 use investigational administration route ) randomize trial conduct subject age 18 60 year . The subject receive three vaccine injection 1-year interval .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Orthomyxoviridae Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria : Subject age 18 57 year ( i.e. , less 60 last vaccination ) For woman childbearing potential , negative urine pregnancy test V # 01 Use effective contraception prior trial Subject available trial period Subject able read understand inform consent form Informed consent form sign date subject prior protocolrequired intervention ( Visit 05 Visit 07 , respectively ) . Exclusion Criteria : Selfreported allergy egg protein , chick protein , constituent vaccine , particular , neomycin , formaldehyde , octoxinol 9 Acute febrile disease within 72 hour precede V # 01 , axillary temperature &gt; 37.5°C day inclusion , prior vaccination ( &gt; 37.0°C Czech Republic ) Subject aggravation exist chronic illness ( heart disease , respiratory disease , etc . ) Vaccination influenza within 6 month precede V # 01 Any vaccination within 28 day precede V # 01 schedule V # 01 V # 02 Breastfeeding Immunosuppressive therapy include long term systemic corticotherapy ( 20 mg/day prednisolone equivalent &gt; 2 week ) cancer therapy within month precede V # 01 ongoing Immunoglobulin injection within 3 month precede V # 01 Subject take part plan take part another clinical trial ( 3 month trial duration ) Subject receive extracted pituitary hormone Subjects participate GID01 study ( Lithuanian center )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>57 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Orthomyxoviridae Infection</keyword>
	<keyword>Inactivated , Split-virion influenza vaccine</keyword>
	<keyword>Intradermal injection</keyword>
	<keyword>Adults .</keyword>
</DOC>